患有小细胞肺癌脑转移的患者的患病率,治疗模式和生存率:使用TrinetX瘤学数据库进行的一项回顾性研究
Megan Parker1, Anita Kalluri1, Kelly Jiang1
1Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Neuro-oncology practice
|March 20, 2025
概括
大脑转移 (BM) 影响35%的小细胞肺癌 (SCLC) 患者,通常呈现出晚期疾病. 一旦诊断出大脑转移,SCLC患者的生存率仍然很差,无论时间如何.
科学领域:
- 在瘤学瘤学.
- 神经学 神经学
- 癌症研究 癌症研究
背景情况:
- 大脑转移 (BM) 在小细胞肺癌 (SCLC) 患者的发病率和死亡率显著增加.
- 了解SCLC中BM的特征和结果对于改善患者护理至关重要.
研究的目的:
- 调查过去十年中SCLC患者的BM的患病率,时间,治疗模式和生存结果.
- 为了比较SCLC患者的人口统计和临床特征,有和没有BM.
主要方法:
- 来自TriNetX瘤学数据库的4014名SCLC患者的回顾性分析.
- 使用奇平方和t测试对临床和人口学变量进行比较.
- 在倾向得分匹配后,使用卡普兰-梅尔和考克斯回归的整体生存 (OS) 分析.
主要成果:
- 35.0%的SCLC患者发展了BM (9.9%是同步的,21.2%是元时的,3.9%是早发的).
- 结核病患者年轻,更有可能是黑人/非洲裔美国人,并且呈现出更先进的阶段.
- 同步的BM与SCLC后诊断的较低的OS相关,但OS在BM诊断后或与单独的额外头转移相比没有区别.
结论:
- 患有BM的SCLC患者的生存结果很差,不管BM何时被诊断出来.
- 肌肉瘤的存在使得SCLC患者的预后不佳.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...